期刊文献+

从血液透析的角度看肝素诱导的血小板减少症 被引量:9

下载PDF
导出
摘要 肝素诱导的血小板减少症(heparin-induced thrombocytopenia,HIT)是使用普通肝素或低分子肝素的副反应,其特征是血小板减少同时伴有动静脉血栓形成的高风险。临床上HIT并不少见,而被诊断并得到治疗的却很少。HIT的发生与HIT抗体的产生密切相关,而血液透析患者中HIT抗体阳性是否会导致患者死亡率增加仍存在争议。HIT的诊断基于临床表现和实验室检查。HIT的实验室检查主要包括监测血小板计数和血清学检查方法2大类,4T临床评分系统对诊断HIT有一定的指导意义。对于临床高度怀疑HIT的患者,应立即停所有肝素制剂、转换抗凝剂、进行相应的实验室检查、仔细监测血栓事件、避免预防性输注血小板。
出处 《中国血液净化》 2011年第12期681-685,共5页 Chinese Journal of Blood Purification
基金 国家自然科学基金(30770861 30971369) 人事部留学回国人员优秀项目
  • 相关文献

参考文献26

  • 1Warkentin TE.Heparin-induced thrombocytopenia:diagnosis and management[J].Circulation,2004,110:e454-458.
  • 2Cook D,Meade M,Guyatt G,et al.Dalteparin versus unfractionated heparin in critically ill patients[J].N Engl J Med,2011,364:1305-1314.
  • 3Rice L Heparin-induced thrombocytopenia:myths and misconceptions (that will cause trouble for you and your patient)[J].Arch Intern Med,2004,164:1961-1964.
  • 4Levy JH,Hursting MJ.Heparin-induced thrombocytopenia,a prothrombotic disease[J].Hematol Oncol Clin North Am,2007,21:65-88.
  • 5Syed S,Reilly RF.Heparin-induced thrombocytopenia:a renal perspective[J].Nat Rev Nephrol,2009,5:501-511.
  • 6Yamamoto S,Koide M,Matsuo M,et al.Heparin-induced thrombocytopenia in hemodialysis patients[J].Am J Kidney Dis,1996,28:82-85.
  • 7高亚玥,赵永强,王书杰.肝素制剂应用患者中血小板减少症的发病率及病因分析[J].中日友好医院学报,2010,24(4):198-201. 被引量:15
  • 8Brieger DB,Mak KH,Kottke-Marchant K,et al.Heparin-induced thrombocytopenia[J].Am Coll Cardiol,1998,31:1449-1459.
  • 9Warkentin TE.New approaches to the diagnosis of hepa-rininduced thrombocytopenia[J].Chest,2005,127(2 Suppl):35S-45S.
  • 10Warkentin TE,Greinacher A.Heparin-induced thromboc-ytopenia:recognition,treatment,and prevention:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):311S-337S.

二级参考文献38

  • 1宣可平,张晓红.肝素诱导的血小板减少症诊治进展[J].国外医学(输血及血液学分册),2005,28(3):253-256. 被引量:10
  • 2Warkentin TE, Chong BH, Greinacher A. Heparin induced thrombocytopenia: toward consensus[J]. Thromb Haemost, 1998, 79:1-7.
  • 3Chong BH, Castaldi PA. Platelet proaggregating effects of heparin: possible mechanism for non-immune heparin associated thrombocytopenia[J]. Aust NZ J Med, 1986,16:715- 716.
  • 4Gurbuz AT, Elliott WG, Zia AA. Heparin induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines[J]. Eur J Cardiothorac Surg ,2005, 27:138-149.
  • 5Arnold DM, Kelton JG. Heparin-induced thrombocytopenia: an iceberg rising[J]. Mayo Clin Proc, 2005,80:988-990.
  • 6Suvarna S, RauovaL, McCrackenEK, et al. PF4/heparin complexes are T cell-dependent antigens[J]. Blood, 2005,106: 929-931.
  • 7Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti PF4- heparin antibodies to platelets and the resultant platelet activation[J]. Blood, 2000,96:182-187.
  • 8Suh JS, Aster RH, Visentin GP. Antibodies from patients with beparin-induced thrombocytopenia/thrombosis recog nize different epitopes on heparin: platelet factor 4[J]. Blood .1998. 91:916-922.
  • 9Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor4/heparin antibodies from patients with heparin induced thrombocytopenia provoke direct activation of microvascular endothelial cells[J]. Int Immunol, 2002, 14: 121-129.
  • 10Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells[J]. J Clin Invest ,1994,93: 81-88.

共引文献29

同被引文献80

引证文献9

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部